NCT07544056 2026-04-22
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
BeBetter Med Inc
Phase 2/3 Not yet recruiting
BeBetter Med Inc
RemeGen Co., Ltd.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Chengdu Kanghong Biotech Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nanjing Leads Biolabs Co.,Ltd
University Medical Center Groningen
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.